Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Significant efforts to develop pharmacogenomic predictors have been made to guide more effective and safer chemotherapy. Although a considerable amount of data has been generated from numerous experimental or clinical studies, there is a large gap between pharmacogenomic knowledge and clinical application. This review will focus on eight pharmacogenetic tests including TYMS, DPYD, UGT1A1, CYP2D6, EGFR, KRAS, FCGR3A, and BRCA1/2 to predict toxicity or response to commonly used chemotherapeutic agents. We will discuss the current level of evidence, if the current pharmacogenetic tests are appropriate for clinical application, and how to integrate the pharmacogenomic information into routine clinical practice.
Lee
Soo-Youn
SY
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
McLeod
Howard L
HL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005472:Fluorouracil / Q000627:therapeutic use; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods*; D013629:Tamoxifen / Q000627:therapeutic use; D000099148:UGT1A1 Enzyme
D000970:Antineoplastic Agents; D002166:Camptothecin; D019389:Cytochrome P-450 CYP2D6; D066246:ErbB Receptors; D005472:Fluorouracil; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D013629:Tamoxifen; D000099148:UGT1A1 Enzyme; C512478:EGFR protein, human